Strecker E P, Ostheim-Dzerowycz W, Boos I B
Department of Radiology, Diakonissen Hospital, Diakonissenstrasse 28, D-76199 Karlsruhe, Germany.
Cardiovasc Intervent Radiol. 1998 Mar-Apr;21(2):109-15. doi: 10.1007/s002709900225.
To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial infusion therapy in patients with severe ischemic limb disease.
Ten patients with deep, extended ischemic ulcerations (all 10) and osteomyelitis (6/10) of the foot received intraarterial infusions of prostaglandine E1 and antibiotics, if indicated, via a new port catheter system with the port placed subcutaneously above the groin after percutaneous introduction and the catheter tip placed into the superficial or deep femoral artery.
Port implantation and repeated port access were uncomplicated. During the follow-up period (mean 11 months, range 1 week-50 months), port migration, leakage, or infection was not observed. Three catheters thrombosed and were opened by fibrinolysis with recombinant tissue plasminogen activator instilled via the port. Treatment success was achieved in 8 patients: relief from rest pain (8 patients), reduction of ulcer size (4/8), and complete healing (4/8). Limb savage rate was 80%. In 2 patients amputation could not be avoided.
Selective long-term arterial infusion therapy presents a valuable therapeutic regimen for limb salvage. With the new catheter port system, repeated local intraarterial infusion is safe and simple.
介绍一种新型经皮植入导管端口系统(PIPS)用于重度肢体缺血性疾病患者长期动脉内输注治疗的初步结果。
10例足部有深部、广泛性缺血性溃疡(共10例)且伴有骨髓炎(6/10)的患者,在经皮穿刺并将端口置于腹股沟上方皮下、导管尖端置于股浅动脉或股深动脉后,通过新的端口导管系统接受动脉内前列腺素E1输注及必要时的抗生素输注。
端口植入及重复端口穿刺操作均无并发症。在随访期(平均11个月,范围1周 - 50个月)内,未观察到端口移位、渗漏或感染。3根导管发生血栓形成,通过经端口注入重组组织型纤溶酶原激活剂进行纤溶治疗后开通。8例患者治疗成功:静息痛缓解(8例)、溃疡面积缩小(4/8)、完全愈合(4/8)。肢体挽救率为80%。2例患者截肢无法避免。
选择性长期动脉内输注治疗是一种有价值的肢体挽救治疗方案。使用新型导管端口系统,重复局部动脉内输注安全且简便。